Compare AUDC & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUDC | VYGR |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.0M | 226.8M |
| IPO Year | 1999 | 2015 |
| Metric | AUDC | VYGR |
|---|---|---|
| Price | $8.36 | $3.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $11.67 | ★ $17.00 |
| AVG Volume (30 Days) | 73.0K | ★ 516.9K |
| Earning Date | 02-03-2026 | 11-10-2025 |
| Dividend Yield | ★ 4.62% | N/A |
| EPS Growth | ★ 15.76 | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $244,553,000.00 | $31,316,000.00 |
| Revenue This Year | $2.98 | N/A |
| Revenue Next Year | $3.40 | $71.78 |
| P/E Ratio | $18.61 | ★ N/A |
| Revenue Growth | ★ 0.15 | N/A |
| 52 Week Low | $8.01 | $2.65 |
| 52 Week High | $12.72 | $5.96 |
| Indicator | AUDC | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 32.95 | 39.01 |
| Support Level | $8.71 | $3.81 |
| Resistance Level | $8.94 | $4.24 |
| Average True Range (ATR) | 0.20 | 0.21 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 3.41 | 6.73 |
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.